)
Visual
test
Pharma Mar
Pharma Mar (PHM) investor relations material
Pharma Mar Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary2 Mar, 2026
Strategic vision and leadership in marine oncology
Focused on developing and commercializing anticancer drugs derived from marine sources, aiming to remain a global leader in marine medicinal innovation.
Mission centers on improving cancer patient outcomes through novel therapies inspired by the sea.
Product portfolio and pipeline
Three approved oncology products: Yondelis (trabectedin), Aplidin (plitidepsin), and Zepzelca (lurbinectedin), with established European sales force.
Diversified pipeline includes late- and early-stage assets, with ongoing development in solid tumors and soft tissue sarcomas.
Lurbinectedin is positioned as standard of care in 2nd line SCLC in the US and emerging in 1st line maintenance.
Clinical development and trial results
IMforte Phase 3 trial showed statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) for lurbinectedin plus atezolizumab in extensive-stage SCLC.
Safety profile of lurbinectedin plus atezolizumab was manageable, with most adverse events not leading to discontinuation.
LAGOON Phase 3 trial in relapsed SCLC completed recruitment, with topline data expected in 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pharma Mar
- Revenue up 27% and net profit up 187%, driven by Zepzelca and oncology milestones.PHM
Q4 202527 Feb 2026 - Net profit rose to €26.2M as revenue, royalties, and licensing income hit record highs.PHMQ4 202412 Feb 2026
- Revenue up 8% and EBITDA up 14%, with strong R&D and positive trial results.PHMQ3 202412 Feb 2026
- Revenue up 1% to €80.8M, net profit €3.5M, royalties up 16%, and R&D spend increased.PHMQ2 202412 Feb 2026
- Recurring revenue up 19%, EBITDA up 60%, and strong cash position at €142.2M.PHMQ1 202512 Feb 2026
- Revenue up 18% to €95.3M, EBITDA €25.1M, driven by oncology sales and licensing gains.PHMQ2 202512 Feb 2026
- Net income and EBITDA surged, fueled by oncology sales, FDA milestones, and licensing deals.PHMQ3 202512 Feb 2026
- IMforte Phase 3 results drive FDA Priority Review and rapid EU uptake for lurbinectedin combo.PHMStatus Update13 Nov 2025
Next Pharma Mar earnings date
Q1 202624 Apr, 2026
Pharma Mar
Next Pharma Mar earnings date
Q1 202624 Apr, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage